Daily Cosmetic Research Analysis
A multicenter double-blind randomized split-face trial shows cold-crosslinked hyaluronic acid fillers achieve 12-month efficacy and safety with superiority to a leading comparator for nasolabial folds. A systematic review finds robotic nipple-sparing mastectomy improves aesthetic outcomes with comparable oncologic safety but higher cost and operative time. A global medicolegal systematic review identifies unsatisfactory results, inadequate consent, and follow-up as leading drivers of litigation
Summary
A multicenter double-blind randomized split-face trial shows cold-crosslinked hyaluronic acid fillers achieve 12-month efficacy and safety with superiority to a leading comparator for nasolabial folds. A systematic review finds robotic nipple-sparing mastectomy improves aesthetic outcomes with comparable oncologic safety but higher cost and operative time. A global medicolegal systematic review identifies unsatisfactory results, inadequate consent, and follow-up as leading drivers of litigation in facial aesthetic surgery.
Research Themes
- Aesthetic injectables and biomaterials
- Robotic oncoplastic breast surgery and cosmetic outcomes
- Medicolegal risk mitigation in facial aesthetic surgery
Selected Articles
1. Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study.
In a multicenter double-blind randomized split-face trial (N=140), cold-crosslinked HA fillers (EVLF, EVLS) achieved noninferiority and statistical superiority versus Restylane-L on WSRS at 6 months, with EVLF maintaining superiority through 12 months. Patient-reported outcomes (FACE-Q) improved significantly at all time points and treatments were well tolerated.
Impact: This high-quality RCT provides head-to-head evidence that a novel cold-crosslinking process yields durable, superior aesthetic correction with good tolerability, informing regulatory decisions and clinical choice of fillers.
Clinical Implications: Cold-crosslinked HA fillers can be considered first-line options for nasolabial folds, offering year-long efficacy and favorable patient satisfaction. Clinicians can counsel patients on durability and safety compared with an established comparator.
Key Findings
- Primary endpoint: cold-crosslinked fillers achieved noninferiority and statistical superiority versus Restylane-L on WSRS at Month 6.
- EVLF showed statistically superior WSRS improvements at all visits through 12 months; EVLS at 6 and 9 months.
- FACE-Q scores improved significantly from baseline (P < .0001) at all time points; treatments were well tolerated.
Methodological Strengths
- Multicenter, randomized, controlled, double-blind, split-face design
- Blinded evaluator assessments and validated patient-reported outcomes (FACE-Q) with 12-month follow-up
Limitations
- Single comparator (Restylane-L) and single indication (nasolabial folds) limit generalizability
- Optional retreatment at 12 months and lack of data beyond 12–15 months constrain long-term conclusions
Future Directions: Head-to-head trials across additional facial indications and comparators, longer-term safety/immunogenicity surveillance, and mechanistic studies on cold-crosslinking properties.
BACKGROUND: Evolysse Form (EVLF) and Evolysse Smooth (EVLS) (Symatese, Chaponost, France) are new hyaluronic acid fillers created using an innovative cold-crosslinking process. OBJECTIVES: The authors of this study aim to collect safety and effectiveness data on new cold-crosslinked fillers to support the US approval for the correction of moderate-to-severe dynamic facial wrinkles and folds. METHODS: In this randomized, controlled, split-face study, 140 patients with moderate-to-severe nasolabial folds (NLFs) received a cold-crosslinked filler in 1 NLF (EVLF = 70, EVLS = 70) and a traditionally crosslinked filler, Restylane-L (RESL), in the contralateral fold and were followed through 12 months with an optional retreatment at that time point and subsequent 3 months of safety follow-up. RESULTS: The primary endpoint of mean Wrinkle Severity Rating Scale change from baseline to Month 6 as rated by the photographic review panel demonstrated noninferiority and statistical superiority for the cold-crosslinked fillers. Blinded evaluator Wrinkle Severity Rating Scale assessments showed a mean change from baseline that was statistically significantly better than RESL for EVLF at all visits through 12 months and for EVLS at 6 and 9 months. Most patients were responders on the Global Aesthetic Improvement Scale throughout the study, according to ratings by blinded evaluators, treating investigators, and patients. The FACE-Q appraisal of NLFs' overall mean score showed significant improvement from baseline (P < .0001) at all time points through Month 12 for all treatment groups. All treatments were well tolerated. CONCLUSIONS: The new cold-crosslinked fillers were shown to be safe and effective for correction of NLFs, with results lasting for 1 year.
2. Robotic nipple-sparing mastectomy: a comparative analysis with conventional and endoscopic techniques through a systematic review.
This OSF-registered systematic review (12 studies) found that robotic nipple-sparing mastectomy yields superior cosmetic outcomes (concealed scars, higher 1-year satisfaction) and fewer severe complications such as NAC necrosis, with comparable oncologic safety. Trade-offs include longer operative time and higher per-procedure cost that may diminish with experience.
Impact: Synthesizing comparative data across techniques clarifies the aesthetic and safety profile of R-NSM, guiding patient selection and informing cost–benefit discussions in oncoplastic surgery.
Clinical Implications: For selected patients prioritizing cosmetic outcomes, R-NSM can be considered when resources and expertise are available, with counseling on higher cost and operative time but similar oncologic safety.
Key Findings
- R-NSM improved aesthetic outcomes with concealed scars and higher 1-year patient satisfaction (p=0.03).
- Oncologic endpoints (recurrence, survival, positive margins) were comparable across NSM techniques.
- R-NSM incurred longer operative times (+25–60 min) and higher costs (+$3,700–$5,000), with reduced intraoperative blood loss and lower risk of severe complications including NAC necrosis.
Methodological Strengths
- Prospectively registered (OSF) systematic review with broad database coverage and no language restrictions
- Quality appraisal using QualSyst with reported high scores (0.75–0.95)
Limitations
- Predominantly observational evidence with only two clinical trials; heterogeneity in techniques and outcomes
- Cost and length-of-stay estimates vary and are subject to learning curve effects and institutional factors
Future Directions: Conduct adequately powered RCTs, standardize outcome measures (aesthetic, functional, oncologic), and perform cost-effectiveness analyses to define indications and optimize training pathways.
Robotic nipple-sparing mastectomy (R-NSM) has emerged as an innovative approach in breast cancer surgery, offering improved aesthetic outcomes and patient satisfaction. However, its adoption remains controversial due to limited regulatory approval, higher costs, and the need for further comparative evidence. This systematic review aims to evaluate and compare conventional, endoscopic, and robotic NSM techniques to clarify their respective benefits, limitations, and outcomes. Following OSF registration (osf.io/6xt4s), a systematic review was conducted, identifying studies on nipple-sparing mastectomy (NSM) across multiple databases (January 2025). No language or data availability restrictions were applied. Study quality was assessed using the QualSyst criteria (range: 0.0-1.0). Twelve studies met inclusion criteria (ten observational, two clinical trials), with quality scores ranging from 0.75 to 0.95. R-NSM was associated with longer operative times (+ 25-60 min) and higher costs (+ $3,700-$5,000 per procedure). However, it demonstrated superior aesthetic outcomes, with concealed scars and higher patient satisfaction at 1-year follow-up (p = 0.03). Oncologic safety was comparable among NSM techniques, with no significant differences in recurrence, survival, or positive margin rates. While R-NSM initially resulted in prolonged hospital stays (+ 1.5-3 days), this effect diminished with surgical experience. In addition, R-NSM was linked to reduced intraoperative blood loss and a lower risk of severe postoperative complications, particularly nipple-areola complex necrosis. R-NSM offers promising benefits in selected patients, particularly regarding cosmetic outcomes and reduced complications. However, challenges remain, including high costs, longer surgical times, and the need for standardized protocols. Future research should focus on optimizing surgical techniques, refining patient selection, and conducting high-quality randomized controlled trials to establish its definitive role in breast cancer management.
3. The Medicolegal Challenges of Facial Plastic Surgery: A Systematic Review.
Across 27 studies, leading litigation triggers in facial aesthetic surgery were unsatisfactory results, inadequate informed consent, technical errors, and poor postoperative follow-up, with higher rates in high-volume, highly regulated countries. Emphasis on robust consent processes, postoperative monitoring, and technical precision is essential to reduce malpractice risk.
Impact: Provides a global synthesis of medicolegal risks specific to facial aesthetic surgery, informing consent frameworks, quality improvement, and risk management strategies.
Clinical Implications: Clinicians should standardize comprehensive informed consent, document expectations and risks, optimize postoperative follow-up, and audit technical processes to reduce litigation exposure.
Key Findings
- Primary litigation drivers: unsatisfactory aesthetic outcomes, failure of informed consent, technical errors, and inadequate postoperative follow-up.
- Higher litigation rates occurred in countries with high plastic surgery volumes and stringent regulations.
- Risk mitigation hinges on robust consent processes, close postoperative monitoring, and technical precision.
Methodological Strengths
- Comprehensive multi-database search (2020–2024) including global datasets
- Synthesis across diverse facial aesthetic procedures and >10 countries
Limitations
- Heterogeneity of legal case reporting and lack of standardized outcome metrics preclude meta-analysis
- Predominantly retrospective case sources with potential publication and selection biases
Future Directions: Develop standardized reporting for complications and legal outcomes, establish prospective registries, and evaluate the impact of enhanced consent and follow-up pathways on litigation rates.
Facial plastic surgery is associated with a growing number of medicolegal challenges, particularly because of postoperative complications and patient dissatisfaction. This systematic review aimed to examine the medicolegal challenges associated with facial plastic surgery, focusing on postoperative complications, patient dissatisfaction, litigation cases, and medicolegal risk factors. A comprehensive literature search was conducted in MEDLINE (National Library of Medicine, Bethesda, MD), Embase (Elsevier, Amsterdam, the Netherlands), Cochrane Library (Wiley, Hoboken, NJ), PubMed (National Library of Medicine), Web of Science (Clarivate Analytics, Philadelphia, PA), SCOPUS (Elsevier), and Google Scholar (Alphabet Inc., Mountain View, CA) from 2020 to 2024. Medicolegal cases related to facial aesthetic surgeries were included. In total, 27 studies met the inclusion criteria. The leading causes of litigation included unsatisfactory aesthetic outcomes, failure of informed consent, technical surgical errors, and inadequate postoperative follow-up. The highest litigation rates were reported in countries with high volumes of plastic surgery cases and stringent regulations. This review highlights the increasing medicolegal burden in aesthetic surgery. Informed consent, postoperative monitoring, and technical precision are crucial for mitigating risks and preventing malpractice claims. The study synthesized medicolegal trends across all major facial aesthetic surgeries. It incorporated a global perspective, analyzing litigation data from over 10 countries, which is uncommon in most similar studies.